{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T05:53:06Z","timestamp":1747201986534,"version":"3.40.5"},"reference-count":57,"publisher":"Federacion Colombiana de Obstetricia y Ginecologia","issue":"3","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Colomb. Obstet. Ginecol."],"abstract":"<jats:p>Objetivo: describir el caso de una paciente con S\u00edndrome de Li-Fraumeni (SLF) y c\u00e1ncer de mama, en quien se cuestion\u00f3 el beneficio en la supervivencia de la mastectom\u00eda profil\u00e1ctica contralateral (MPC); asimismo, se pretende hacer una discusi\u00f3n cr\u00edtica acerca de la evidencia que soporta este procedimiento en esta poblaci\u00f3n.\r\nPresentaci\u00f3n del caso: mujer de 37 a\u00f1os con c\u00e1ncer de mama y m\u00faltiples antecedentes familiares de c\u00e1nceres de temprana aparici\u00f3n del espectro del SLF, en quien, durante la adyuvancia hormonal, se confirm\u00f3 una variante patog\u00e9nica en el gen TP53. La paciente fue presentada en la Junta Multidisciplinaria del Servicio de Mama de un Centro Oncol\u00f3gico de referencia en Colombia, con el fin de discutir el beneficio de la MPC. La decisi\u00f3n de la junta fue no realizar la MPC. Despu\u00e9s de 30 meses de seguimiento la paciente se encuentra libre de enfermedad.\r\nConclusi\u00f3n: no existe evidencia que analice, de forma particular, el impacto de la MPC en la supervivencia de las pacientes con SLF y c\u00e1ncer de mama. Sin embargo, a la luz del conocimiento actual no es posible generalizar la conducta de omitir esta cirug\u00eda profil\u00e1ctica. Es importante reportar los casos en los que se decida realizar u omitir este procedimiento con el fin de incrementar el cuerpo de la evidencia, dado que existen limitaciones para construir grandes cohortes o estudios experimentales exclusivos para esta alteraci\u00f3n gen\u00e9tica.<\/jats:p>","DOI":"10.18597\/rcog.3690","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T17:36:53Z","timestamp":1635183413000},"page":"307-318","source":"Crossref","is-referenced-by-count":0,"title":["Revisitando la indicaci\u00f3n de la mastectom\u00eda profil\u00e1ctica contralateral en pacientes con S\u00edndrome de Li-Fraumeni y c\u00e1ncer de mama. Reporte de un caso"],"prefix":"10.18597","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0951-349X","authenticated-orcid":false,"given":"Ximena","family":"Brice\u00f1o-Morales","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7886-2565","authenticated-orcid":false,"given":"Clara","family":"Brice\u00f1o-Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3104-3567","authenticated-orcid":false,"given":"Silvia In\u00e9s","family":"Guerrero-Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0080-9200","authenticated-orcid":false,"given":"Ana Mar\u00eda","family":"Pedroza-Dur\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1022-6946","authenticated-orcid":false,"given":"Ra\u00fal Alexis","family":"S\u00faarez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7913","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"key":"87789","unstructured":"Schneider K, Zelley K, Nichols KE, Garber J. Li-Fraumeni Syndrome. Seattle (WA): In: Adam MP, Ardinger HH, Pagon RA, et al., editors; 1999. Disponible en: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1311\/"},{"key":"87790","doi-asserted-by":"crossref","unstructured":"Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med. 1969;71(4):747-52. https:\/\/doi.org\/10.7326\/0003-4819-71-4-747","DOI":"10.7326\/0003-4819-71-4-747"},{"key":"87791","doi-asserted-by":"crossref","unstructured":"Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250(4985):1233-8. https:\/\/doi.org\/10.1126\/science.1978757","DOI":"10.1126\/science.1978757"},{"key":"87792","doi-asserted-by":"crossref","unstructured":"Hwang SJ, Lozano G, Amos CI, Strong LC. Germline p53 mutations in a cohort with childhood sarcoma: Sex differences in cancer risk. Am J Hum Genet. 2003;72(4):975\u201383. https:\/\/doi.org\/10.1086\/374567","DOI":"10.1086\/374567"},{"key":"87793","doi-asserted-by":"crossref","unstructured":"Id Said B, Kim H, Tran J, Novokmet A, Malkin D. Super-Transactivation TP53 Variant in the Germline of a Family with Li-Fraumeni Syndrome. Hum Mutat [Internet]. 2016;37(9):889\u201392. https:\/\/doi.org\/10.1158\/1538-7445.AM2016-792","DOI":"10.1002\/humu.23025"},{"key":"87794","doi-asserted-by":"crossref","unstructured":"Kuba MG, Lester SC, Bowman T, Stokes SM, Taneja KL, Garber JE, et al. Histopathologic features of breast cancer in Li\u2013Fraumeni syndrome. Mod Pathol. 2021;34(3):542\u20138. https:\/\/doi.org\/10.1038\/s41379-020-0610-4","DOI":"10.1038\/s41379-020-0610-4"},{"key":"87795","unstructured":"Sidransky D, Tokino T, Helzlsouer K, Zehnbauer B, Shelton B, Prestigiacomo L, et al. Inherited p53 Gene Mutations in Breast Cancer. Cancer Res. 1992;52(10):2984\u20136."},{"key":"87796","doi-asserted-by":"crossref","unstructured":"Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer. 2016;122(23):3673\u201381. https:\/\/doi.org\/10.1002\/cncr.30248","DOI":"10.1002\/cncr.30248"},{"key":"87797","doi-asserted-by":"crossref","unstructured":"Masciari S, Dillon DA, Rath M, Robson M, Weitzel JN, Balmana J, et al. Breast cancer phenotype in women with TP53 germline mutations: A Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat. 2012;133(3):1125\u201330. https:\/\/doi.org\/10.1007\/s10549-012-1993-9","DOI":"10.1007\/s10549-012-1993-9"},{"key":"87798","unstructured":"Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res. 1994;54(5):1298\u2013304. Disponible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8118819"},{"key":"87799","unstructured":"Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res [Internet]. 2003;63(20):6643\u201350. Disponible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/14583457"},{"key":"87800","doi-asserted-by":"crossref","unstructured":"Packwood K, Martland G, Sommerlad M, Shaw E, Moutasim K, Thomas G, et al. Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study). J Pathol Clin Res. 2019;5(3):189\u201398. https:\/\/doi.org\/10.1002\/cjp2.133","DOI":"10.1002\/cjp2.133"},{"key":"87801","doi-asserted-by":"crossref","unstructured":"Kwong A, Shin VY, Ho CYS, Au CH, Slavin TP, Weitzel JN, et al. Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients. BMC Cancer. 2020;20(1):1\u201310. https:\/\/doi.org\/10.1186\/s12885-020-07476-y","DOI":"10.1186\/s12885-020-07476-y"},{"key":"87802","doi-asserted-by":"crossref","unstructured":"Breast Cancer Association Consortium Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med. 2021;384(5):428-439. https:\/\/doi.org\/10.1056\/NEJMoa1913948","DOI":"10.1056\/NEJMoa1913948"},{"key":"87803","doi-asserted-by":"crossref","unstructured":"Evans DG, Woodward ER. New surveillance guidelines for Li-Fraumeni and hereditary TP53 related cancer syndrome: implications for germline TP53 testing in breast cancer. Fam Cancer. 2021;20(1):1\u20137. https:\/\/doi.org\/10.1007\/s10689-020-00207-z","DOI":"10.1007\/s10689-020-00207-z"},{"key":"87804","doi-asserted-by":"crossref","unstructured":"Kwong A, Shin VY, Ho CYS, Au CH, Slavin TP, Weitzel JN, et al. Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients. BMC Cancer. 2020;20(1):1\u201310. https:\/\/doi.org\/10.1186\/s12885-020-07476-y","DOI":"10.1186\/s12885-020-07476-y"},{"key":"87805","doi-asserted-by":"crossref","unstructured":"Krontiras H, Farmer M, Whatley J. Breast Cancer Genetics and Indications for Prophylactic Mastectomy. Surg Clin North Am. 2018;98(4):677\u201385. https:\/\/doi.org\/10.1016\/j.suc.2018.03.004","DOI":"10.1016\/j.suc.2018.03.004"},{"key":"87806","doi-asserted-by":"crossref","unstructured":"Alves MC, Sandoval RL, Pisani JP, Quirino CV, Santos ES, Achatz MI. Abstract P6-08-18: Breast cancer in Li-Fraumeni syndrome and risk-reduction mastectomy in TP53 p.R337H carriers. In: Poster Session Abstracts. American Association for Cancer Research; 2020. p. P6-08-18-P6-08\u201318. https:\/\/doi.org\/10.1158\/1538-7445.SABCS19-P6-08-18","DOI":"10.1158\/1538-7445.SABCS19-P6-08-18"},{"key":"87807","doi-asserted-by":"crossref","unstructured":"Kratz CP, Achatz MI, Brugieres L, Frebourg T, Garber JE, Greer MLC, et al. Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin Cancer Res. 2017;23(11):e38\u201345. https:\/\/doi.org\/10.1158\/1538-7445.SABCS19-P6-08-18","DOI":"10.1158\/1078-0432.CCR-17-0408"},{"key":"87808","doi-asserted-by":"crossref","unstructured":"Fortuno C, Pesaran T, Mester J, Dolinsky J, Yussuf A, McGoldrick K, et al. Genotype-phenotype correlations among TP53 carriers: Literature review and analysis of probands undergoing multi-gene panel testing and single-gene testing. Cancer Genet. 2020;248\u2013249:11\u20137. https:\/\/doi.org\/10.1016\/j.cancergen.2020.09.002","DOI":"10.1016\/j.cancergen.2020.09.002"},{"key":"87809","doi-asserted-by":"crossref","unstructured":"Sheng S, Xu Y, Guo Y, Yao L, Hu L, Ouyang T, et al. Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer. Int J Cancer. 2020;146(2):487\u201395. https:\/\/doi.org\/10.1002\/ijc.32424","DOI":"10.1002\/ijc.32424"},{"key":"87810","doi-asserted-by":"crossref","unstructured":"Song CV, Teo SH, Taib NA, Yip CH. Surgery for BRCA, TP53 and PALB2: A literature review. Ecancermedicalscience. 2018;12:1\u201310. https:\/\/doi.org\/10.3332\/ecancer.2018.863","DOI":"10.3332\/ecancer.2018.863"},{"key":"87811","doi-asserted-by":"crossref","unstructured":"Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev. 2018;4(4):CD002748. https:\/\/doi.org\/10.1002\/14651858","DOI":"10.1002\/14651858.CD002748.pub4"},{"key":"87812","doi-asserted-by":"crossref","unstructured":"Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2010;(11):CD002748. https:\/\/doi.org\/10.1002\/14651858.CD002748","DOI":"10.1002\/14651858.CD002748.pub3"},{"key":"87813","doi-asserted-by":"crossref","unstructured":"Eck DL, Perdikis G, Rawal B, Bagaria S, McLaughlin SA. Incremental risk associated with contralateral prophylactic mastectomy and the effect on adjuvant therapy. Ann Surg Oncol. 2014;21(10):3297-303. https:\/\/doi.org\/10.1245\/s10434-014-3903-3","DOI":"10.1245\/s10434-014-3903-3"},{"key":"87814","doi-asserted-by":"crossref","unstructured":"Gentile M, Bergman Jungestr\u00f6m M, Olsen KE, S\u00f6derkvist P, Wingren S. p53 and survival in early onset breast cancer: Analysis of gene mutations, loss of heterozygosity and protein accumulation. Eur J Cancer. 1999;35(8):1202\u20137. https:\/\/doi.org\/10.1016\/S0959-8049(99)00121-5","DOI":"10.1016\/S0959-8049(99)00121-5"},{"key":"87815","unstructured":"Soussi T. UMD TP53 Mutation Database. The TP53 Web Site. 2017. Disponible en: https:\/\/p53.fr\/the-database"},{"key":"87816","doi-asserted-by":"crossref","unstructured":"Ossa CA, Molina G, Cock-Rada AM. S\u00edndrome de li-fraumeni. Biomedica. 2016;36(2):182\u20137. https:\/\/doi.org\/10.7705\/biomedica.v36i3.2793","DOI":"10.7705\/biomedica.v36i3.2793"},{"key":"87817","doi-asserted-by":"crossref","unstructured":"Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, et al. Genetic\/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2021. JNCCN J Natl Compr Cancer Netw. 2021;19(1):77\u2013102. https:\/\/doi.org\/10.6004\/jnccn.2021.0001","DOI":"10.6004\/jnccn.2021.0001"},{"key":"87818","doi-asserted-by":"crossref","unstructured":"Schon K, Tischkowitz M. Clinical implications of germline mutations in breast cancer: TP53. Breast Cancer Res Treat. 2018;167(2):417\u201323. https:\/\/doi.org\/10.1007\/s10549-017-4531-y","DOI":"10.1007\/s10549-017-4531-y"},{"key":"87819","doi-asserted-by":"crossref","unstructured":"Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JR, et al. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Oncol. 2020;38(18):2080\u2013106. https:\/\/doi.org\/10.1200\/JCO.20.00299","DOI":"10.1200\/JCO.20.00299"},{"key":"87820","unstructured":"Calder\u00f3n del Valle SA, Gall\u00f3n Villegas LJ. C\u00e1ncer de mama asociado a mutaciones gen\u00e9ticas de los BRCA 1 y 2. CES Med. 2012;26(2):185\u201399."},{"key":"87821","doi-asserted-by":"crossref","unstructured":"Van Der Groep P, Van Der Wall E, Van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol. 2011;34(2):71\u201388. https:\/\/doi.org\/10.1007\/s13402-011-0010-3","DOI":"10.1007\/s13402-011-0010-3"},{"key":"87822","doi-asserted-by":"crossref","unstructured":"Van Sprundel TC, Schmidt MK, Rookus MA, Brohet R, Van Asperen CJ, Rutgers EJT, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer. 2005;93(3):287\u201392. https:\/\/doi.org\/10.1038\/sj.bjc.6602703","DOI":"10.1038\/sj.bjc.6602703"},{"key":"87823","doi-asserted-by":"crossref","unstructured":"Evans DGR, Ingham SL, Baildam A, Ross GL, Lalloo F, Buchan I, et al. Contralateral mastectomy improves survival in women with BRCA1\/2-associated breast cancer. Breast Cancer Res Treat. 2013;140(1):135\u201342. https:\/\/doi.org\/10.1007\/s10549-013-2583-1","DOI":"10.1007\/s10549-013-2583-1"},{"key":"87824","doi-asserted-by":"crossref","unstructured":"Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: Retrospective analysis. BMJ. 2014;348:1\u201311. https:\/\/doi.org\/10.1136\/bmj.g226","DOI":"10.1136\/bmj.g226"},{"key":"87825","doi-asserted-by":"crossref","unstructured":"Heemskerk-Gerritsen BAM, Rookus MA, Aalfs CM, Ausems MGEM, Coll\u00e9e JM, Jansen L, et al. Improved overall survival after contralateral risk-reducing mastectomy in brca1\/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis. Vol. 136, International Journal of Cancer. 2015. p. 668\u201377. https:\/\/doi.org\/10.1002\/ijc.29032","DOI":"10.1002\/ijc.29032"},{"key":"87826","doi-asserted-by":"crossref","unstructured":"Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018;19(2):169\u201380. https:\/\/doi.org\/10.1016\/S1470-2045(17)30891-4","DOI":"10.1016\/S1470-2045(17)30891-4"},{"key":"87827","unstructured":"Levine DA, Gemignani ML. Prophylactic surgery in hereditary breast\/ovarian cancer syndrome. Vol. 17, ONCOLOGY. 2003."},{"key":"87828","unstructured":"Biglia N, D\u2019Alonzo M, Sgro LG, Tomasi Cont N, Bounous V, Robba E. Breast cancer treatment in mutation carriers: Surgical treatment. Vol. 68, Minerva Ginecologica. 2016."},{"key":"87829","doi-asserted-by":"crossref","unstructured":"Ludwig KK, Neuner J, Butler A, Geurts JL, Kong AL. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg. 2016;212(4):660\u20139. https:\/\/doi.org\/10.1016\/j.amjsurg.2016.06.010","DOI":"10.1016\/j.amjsurg.2016.06.010"},{"key":"87830","doi-asserted-by":"crossref","unstructured":"Fayanju OM, Stoll CRT, Fowler S, Colditz GA, Margenthaler JA. Contralateral prophylactic mastectomy after unilateral breast cancer: A systematic review and meta-analysis. Vol. 260, Annals of Surgery. 2014. https:\/\/doi.org\/10.1097\/SLA.0000000000000769","DOI":"10.1097\/SLA.0000000000000769"},{"key":"87831","doi-asserted-by":"crossref","unstructured":"Valachis A, Nearchou AD, Lind P. Surgical management of breast cancer in BRCA-mutation carriers: A systematic review and meta-analysis. Breast Cancer Res Treat. 2014;144(3):443\u201355. https:\/\/doi.org\/10.1007\/s10549-014-2890-1","DOI":"10.1007\/s10549-014-2890-1"},{"key":"87832","doi-asserted-by":"crossref","unstructured":"Li X, You R, Wang X, Liu C, Xu Z, Zhou J, et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: A meta-analysis and systematic review. Vol. 22, Clinical Cancer Research. 2016. 3971\u20133981 p. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1465","DOI":"10.1158\/1078-0432.CCR-15-1465"},{"key":"87833","unstructured":"American Society of Clinical Oncology (ASCO) - SEER Data Bases. 2021. Disponible en: https:\/\/www.cancer.net\/cancer-types\/sarcomas-soft-tissue"},{"key":"87834","doi-asserted-by":"crossref","unstructured":"Davis FG, McCarthy BJ, Freels S, Kupelian V, Bondy ML. The conditional probability of survival of patients with primary malignant brain tumors. Cancer. 1999;85(2):485\u201391. https:\/\/doi.org\/10.1002\/(SICI)1097-0142(19990115)85:2<485::AID-CNCR29>3.0.CO;2-L","DOI":"10.1002\/(SICI)1097-0142(19990115)85:2<485::AID-CNCR29>3.0.CO;2-L"},{"key":"87835","unstructured":"American Lung Association. Trends in Lung Cancer Morbidity and Mortality American Lung Association Research and Program Services Division November 2014 Table of Contents Trends in Lung Cancer Morbidity and Mortality List of Tables and Figures. 2014. Disponible en: https:\/\/www.lung.org\/assets\/documents\/research\/lc-trend-report.pdf"},{"key":"87836","doi-asserted-by":"crossref","unstructured":"Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA - J Am Med Assoc. 2019;321(3):288\u2013300. https:\/\/doi.org\/10.1001\/jama.2018.19323","DOI":"10.1001\/jama.2018.19323"},{"key":"87837","unstructured":"Statistics adapted from the American Cancer Society\u2019s publications, Cancer Facts & Figures 2021 and Cancer Facts & Figures 2020; the ACS website; and the National Cancer Institute\u2019s Surveillance, Epidemiology, and End Results (SEER) Program. Disponible en: https:\/\/www.cancer.net\/cancer-types\/breast-cancer\/statistics"},{"key":"87838","doi-asserted-by":"crossref","unstructured":"Liederbach E, Piro R, Hughes K, Watkin R, Wang CH, Yao K. Clinicopathologic features and time interval analysis of contralateral breast cancers. Surg (United States). 2015;158(3):676\u201385. https:\/\/doi.org\/10.1016\/j.surg.2015.03.059","DOI":"10.1016\/j.surg.2015.03.059"},{"key":"87839","doi-asserted-by":"crossref","unstructured":"D\u00edaz\u2010Casas SE, Castilla\u2010Tarra JA, Pena\u2010Torres E, Orozco\u2010Ospino M, Mendoza\u2010Diaz S, Nu\u00f1ez\u2010Lemus M, et al. Pathological Response to Neoadjuvant Chemotherapy and the Molecular Classification of Locally Advanced Breast Cancer in a Latin American Cohort. Oncologist. 2019;24(12):1\u201311. https:\/\/doi.org\/10.1634\/theoncologist.2019-0300","DOI":"10.1634\/theoncologist.2019-0300"},{"key":"87840","doi-asserted-by":"crossref","unstructured":"Crosby MA, Garvey PB, Selber JC, Adelman DM, Sacks JM, Villa MT, et al. Reconstructive outcomes in patients undergoing contralateral prophylactic mastectomy. Plast Reconstr Surg. 2011;128(5). https:\/\/doi.org\/10.1097\/PRS.0b013e31822b6682","DOI":"10.1097\/PRS.0b013e31822b6682"},{"key":"87841","doi-asserted-by":"crossref","unstructured":"Miller ME, Czechura T, Martz B, Hall ME, Pesce C, Jaskowiak N, et al. Operative risks associated with contralateral prophylactic mastectomy: A single institution experience. Ann Surg Oncol. 2013;20(13). https:\/\/doi.org\/10.1245\/s10434-013-3108-1","DOI":"10.1245\/s10434-013-3108-1"},{"key":"87842","doi-asserted-by":"crossref","unstructured":"Osman F, Saleh F, Jackson TD, Corrigan MA, Cil T. Increased postoperative complications in bilateral mastectomy patients compared to unilateral mastectomy: An analysis of the NSQIP database. Ann Surg Oncol. 2013;20(10). https:\/\/doi.org\/10.1245\/s10434-013-3116-1","DOI":"10.1245\/s10434-013-3116-1"},{"key":"87843","doi-asserted-by":"crossref","unstructured":"Silva AK, Lapin B, Yao KA, Song DH, Sisco M. The Effect of Contralateral Prophylactic Mastectomy on Perioperative Complications in Women Undergoing Immediate Breast Reconstruction: A NSQIP Analysis. Ann Surg Oncol. 2015;22(11). https:\/\/doi.org\/10.1245\/s10434-015-4628-7","DOI":"10.1245\/s10434-015-4628-7"},{"key":"87844","doi-asserted-by":"crossref","unstructured":"Frost MH, Slezak JM, Tran NV, Williams CI, Johnson JL, Woods JE, et al. Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol. 2005 Nov 1;23(31):7849-56. https:\/\/doi.org\/10.1200\/JCO.2005.09.233","DOI":"10.1200\/JCO.2005.09.233"},{"key":"87845","doi-asserted-by":"crossref","unstructured":"Yao K. Contralateral prophylactic mastectomy: Current perspectives. Chang Paradig Manag Breast Cancer. 2017;33\u201346. https:\/\/doi.org\/10.1007\/978-3-319-60336-0_3","DOI":"10.1007\/978-3-319-60336-0_3"}],"container-title":["Revista Colombiana de Obstetricia y Ginecolog\u00eda"],"original-title":[],"link":[{"URL":"https:\/\/revista.fecolsog.org\/index.php\/rcog\/article\/download\/3690\/3717","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revista.fecolsog.org\/index.php\/rcog\/article\/download\/3690\/3717","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T18:12:03Z","timestamp":1635963123000},"score":1,"resource":{"primary":{"URL":"https:\/\/revista.fecolsog.org\/index.php\/rcog\/article\/view\/3690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":57,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,9,30]]}},"URL":"https:\/\/doi.org\/10.18597\/rcog.3690","relation":{},"ISSN":["2463-0225","0034-7434"],"issn-type":[{"type":"electronic","value":"2463-0225"},{"type":"print","value":"0034-7434"}],"subject":[],"published":{"date-parts":[[2021,9,30]]}}}